Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixchiq in immunocompromised adults with HIV
NCT06028841Phase 3Withdrawn
- Sponsor
- Valneva
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fezolinetant in chikungunya virus infection, sponsored by Valneva. Planned start Apr 2024; status: withdrawn.
02
Drugs
fezolinetant
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT06028841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028841.